Trials (first author, year) | Type of PDR | Dosage of intravitreal bevacizumab | Time prior to pars plana vitrectomy | Type of pars plana vitrectomy | Panretinal photocoagulation | Gas injection | Silicone oil injection | Lens extract | Surgeon |
Yeh 20091 | Active severe PDR: visible large new vessels within the proliferative tissue with fresh preretinal and/or VH | 1.25 mg (0.05 ml) | 7–9 days | PPV | Done |
|
|
| Same |
da R Lucena 20092 | Severe PDR: macula—involving (TRD) | 1.5 mg (0.06 ml) | 2 weeks | 23-gauge PPV | NR |
|
|
| Same |
Rizzo 20083 | Severe PDR: TRD, tractional-rhegmatogenous RD, or TRD complicated with VH | 1.25 mg (0.05 ml) | 5–7 days | 20-gauge PPV | All done |
| 0 | 0 | NR |
Modarres 20094 | Complications of PDR | 2.5 mg (0.1 ml) | 3–5 days | 20-gauge PPV | Done | NR |
| NR | 4 |
Ahmadieh 20095 | Complications of PDR: non-clearing VH, TRD involving or threatening the macula, and active progressive PDR | 1.25 mg (0.05 ml) | 1 week | Standard PPV | NR |
|
| NR | NR |
Yang 20086 | Active PDR | 1.25 mg (0.05 ml) | 7–9 days | Standard PPV | Done |
| 0 |
| Same |
di Lauro 20109 | Active PDR: VH and TRD | 1.25 mg (0.05 ml) | 7 or 20 days | 20-gauge PPV | Done | NR |
| NR | Same |
1–, vitrectomy alone group; 2–, vitrectomy with intravitreal bevacizumab pretreatment; NR, not reported; PDR, proliferative diabetic retinopathy; RD, retinal detachment; TRD, tractional retinal detachment; VH, vitreous haemorrhage.